Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Teva
McKesson
McKinsey
Queensland Health
Medtronic
Johnson and Johnson
Covington
UBS

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021549

« Back to Dashboard

NDA 021549 describes EMEND, which is a drug marketed by Merck, Msd Merck Co, and Merck And Co Inc, and is included in three NDAs. It is available from three suppliers. There are three patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EMEND profile page.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
Summary for 021549
Tradename:EMEND
Applicant:Merck
Ingredient:aprepitant
Patents:2
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021549
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMEND aprepitant CAPSULE;ORAL 021549 NDA Merck Sharp & Dohme Corp. 0006-0461 N 0006-0461-02
EMEND aprepitant CAPSULE;ORAL 021549 NDA Merck Sharp & Dohme Corp. 0006-0461 N 0006-0461-06

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength80MG
Approval Date:Mar 26, 2003TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Aug 28, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Sign UpPatent Expiration:Jul 1, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Jul 1, 2018Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 021549

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Sign Up ➤ Sign Up
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Sign Up ➤ Sign Up
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Sign Up ➤ Sign Up
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Teva
Baxter
Cerilliant
Argus Health
Federal Trade Commission
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.